Recently, the class 1 innovative drug Leritrelvir Tablets (Chinese trade name: 乐睿灵) of Guangdong Raynovent Biotech Co., Ltd is approved for marketing with conditions by China NMPA through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.

The Leritrelvir Teblets are oral small molecular drugs for COVID-19 infection treatment, indicated for adult patients with mild to moderateSARS-CoV-2(COVID-19) infection. Patients should use drugs strictly according to the instructions under the guidance of doctors.

The MAH is asked by NMPA to complete relevant research works of the conditional requirements within a time limit, and submits the follow-up research results as soon as possible.